#4-22E. Predicting MTX Response: The Role of Monocyte Transcriptomes in Arthritis (CMLS, 2026)

Have you ever wished you could accurately predict which inflammatory arthritis patients will respond to methotrexate (MTX) before even starting therapy? In today's episode, we delve into a pivotal study revealing that MTX polyglutamates accumulate in peripheral blood monocytes within just five days of treatment, fundamentally shifting their gene expression toward an anti-inflammatory, aryl-hydrocarbon receptor-driven profile after a month. The study's most groundbreaking discovery is that elevated baseline expression of non-classical monocyte genes—such as FCGR3B and ICAM4—predicts a highly favorable clinical response to MTX. While these transcriptomic signatures offer a powerful predictive tool, we must critically appraise the research; the observational study included a notably small cohort of only 29 patients, meaning these predictive models require rigorous validation in larger, multi-center trials before clinical implementation. For practicing rheumatologists and physicians, this research is highly relevant, as it paves the way for early personalized medicine. By utilizing pretreatment monocyte profiling, we might soon be able to optimize induction therapies, minimizing trial-and-error prescribing and achieving remission faster for our arthritis patients.

Citation: Ríos, I., et al. Monocytes from inflammatory arthritis patients accumulate methotrexate and their transcriptome predicts methotrexate clinical response. Cellular and Molecular Life Sciences. 2026. DOI: 10.1007/s00018-026-06162-9

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.